Months after burying its third and final clinical program, Vical has turned to a reverse merger with Brickell Biotech to put an end to its misery. The new company — in which Vical investors will retain a 40% ownership — will operate under Brickell’s name and agenda.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,